GW 590735

Drug Profile

GW 590735

Alternative Names: 590735; GW-590735

Latest Information Update: 21 Jan 2008

Price : $50

At a glance

  • Originator GlaxoSmithKline; Ligand Pharmaceuticals
  • Class Antihyperlipidaemics; Propionic acids; Small molecules; Thiazoles
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Lipid metabolism disorders

Most Recent Events

  • 18 Jul 2007 GW 590735 is still in active development
  • 31 Dec 2003 Phase-II clinical trials in Lipid metabolism disorders in USA (unspecified route)
  • 31 Dec 2003 Phase-II clinical trials in Atherosclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top